BRD810 is a novel highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models
Rauh, U., Wei, G., Serrano-Wu, M., Kosmidis, G., Kaulfuss, S., Siegel, F., Thede, K., McFarland, J., Poncet-Montange, G., Lemke, T.L., Werbeck, N., Nowak-Reppel, K., Pilari, S., Menz, S., Ocker, M., Kaushik, V., Hubbard, B., Ziegelbauer, K., Golub, T.R.To be published.